Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-32593 Global Partners LP (Exact name of registrant as specified in its charter) Delaware 74-3140887 (State or oth ...

Global Partners LP Common Units (NYSE:GLP) Q2 2024 Results Conference Call August 7, 2024 10:00 AM ET Company Participants Sean Geary - CLO & Secretary Eric Slifka - President & CEO Gregory Hanson - CFO Mark Romaine - COO Conference Call Participants Selman Akyol - Stifel Operator Good day, everyone, and welcome to the Global Partners Second Quarter 2024 Financial Results Conference Call. Today's call is being recorded. [Operator Instructions]. With us from Global Partners are President and Chief Executive ...

aprott/iStock via Getty Images Introduction Hims & Hers (NYSE:HIMS) — the viral telehealth platform that aims to help the world feel great through the power of better health — just reported Q2 earnings that obliterated all expectations. Throughout 2024, the stock has rallied as much as 200%, largely driven by the company's tremendous growth and relentless execution. However, much of the rally was driven by the rising popularity and subsequent shortages of GLP-1 drugs — having recently launched its Weight Lo ...

Exhibit 99.1 GLOBAL PARTNERS LP 800 South Street, Suite 500 P.O. Box 9161 Waltham MA 02454-9161 FOR IMMEDIATE RELEASE Contacts: Gregory B. Hanson Sean T. Geary Chief Financial Officer Chief Legal Officer and Secretary Global Partners LP Global Partners LP (781) 894-8800 (781) 894-8800 Global Partners Reports Second-Quarter 2024 Financial Results Waltham, Mass., August 7, 2024 – Global Partners LP (NYSE: GLP) ("Global" or the "Partnership") today reported financial results for the second quarter ended June 3 ...

MALVERN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced new preclinical data demonstrating the synergistic effect of its lead compound, buntanetap, when combined with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity®) in a mouse model of Alz ...

Hims & Hers stock has been surging since May, but has its valuation gotten too rich? Healthcare stocks don't have to be making weight loss drugs to be hot buys due to the rising demand for glucagon-like peptide 1 (GLP-1) treatments. A good example of that is Hims & Hers Health (HIMS -12.85%). Up more than 140% this year, the telehealth company has been a hot buy with investors not only for its impressive growth but also for its ability to help connect patients with GLP-1 drugs. However, the company's strate ...

Patients who received liraglutide had an 18% slower decline in cognitive function after one year of treatment compared to those who received the placebo. Researchers presented the results on Tuesday at the Alzheimer's Association International Conference in Philadelphia, the world's largest meeting for dementia research. Brian B. Bettencourt | Toronto Star | Getty Images Notably, existing research shows that GLP-1s do not bring the risk of brain swelling and bleeding, two side effects that have been linked ...

Jacob Wackerhausen/iStock via Getty Images Therefore, it could end up being that this recombinant protein from Biohaven could have a synergistic effect with current treatment options. This is possible because of the mechanism of action of this drug compared to the other approved ones. In essence, taldefgrobep alfa is a myostatin inhibitor and its goal is to knock down the signaling of myostatin itself. This is important, because overactive myostatin activation inhibits muscle growth. Thus, the mechanism of ...

1. GZR18 injection is an investigational drug and has not yet been approved in China. In this study, the bi-weekly GZR18 injections were generally safe and well tolerated, consistent with the known safety signals of GLP-1 receptor agonists. The most common adverse events were gastrointestinal reactions, most of which were mild to moderate in severity, comparable to other GLP-1 RAs. In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked second overall and first am ...

Hims & Hers Health (NYSE:HIMS) has slipped back down below $20 after the initial excitement over access to a GLP-1 drug solution has worn off. The online health Source: Finviz Since announcing Q1'24 results in early May, Hims has seen some dramatic news. The online health provider announced the availability of a compound version of Novo Nordisk's (NVO) weight loss medication, and a short report from Hunterbrook Media questioned the business practices of the company. NEW, BIG INVESTIGATION: I felt like death ...